Yıl: 2021 Cilt: 11 Sayı: 2 Sayfa Aralığı: 332 - 335 Metin Dili: İngilizce DOI: 10.5505/kjms.2021.43403 İndeks Tarihi: 01-02-2022

What is Metabolic Surgery? To Whom and When Should It Be Applied?

Öz:
Metabolic syndrome is a cluster of cardiometabolic risk factors that cause some complications. Each component of the syndrome needs to be treated. For this purpose, anti-hypertensive, anti-diabetic, and anti-lipidemic agents are used, but weight control plays a key role in treatment. Exercise, reduction of daily calories with diet and increasing physical activity play a role in the control of body weight. Various medical treatments have been tried, but they have not been very effective. The most effective way is still surgery. Although there is no definite accepted definition of metabolic surgery, it can be defined as surgical interventions to treat metabolic syndrome. The general perception in bariatric surgery is that type 2 diabetes enters remission due to patients’ weight loss. After the operation in these patients, blood sugar control has been shown to be achieved while patients are still in the hospital. It has been understood that the gastrointestinal system plays an essential role in glucose homeostasis, and its mechanisms have been tried to be revealed. The foregut hypothesis and the hindgut hypothesis have been suggested. A hindgut surgery like a duodenal switch has been shown to improve insulin sensitivity and glucose homeostasis without causing a hyperinsulinemic response compared to a foregut surgery like a gastric bypass. Surgeries that modulate the hindgut have more potential to disrupt the absorption of vitamins and minerals than foregut surgeries. To prevent this, the transit bipartition technique has been developed in recent years. As a result, various methods have been used in metabolic surgery. The choice of a surgical technique should be specific to the patient.
Anahtar Kelime:

Metabolik Cerrahi Nedir? Kime ve Ne Zaman Yapılmalıdır?

Öz:
Metabolik sendrom bazı komplikasyonlara neden olan kardiyometabolik risk faktörleri demetidir. Sendromu oluşturan her bileşen tedavi edilmelidir. Bunun için antilipidemik, antidiyabetik, antihipertansif, ilaçlar kullanılır fakat tedavideki kilit rolde kilo kontrolü oynar. Vücut ağırlığının kontrolünde egzersiz, diyetle günlük alınan kalorinin azaltılması ve fiziksel faaliyetlerin artırılması rol oynar. Değişik tıbbi tedavilerlede deneme yapılmış olup çok başarılı olunamamıştır. Hala en etkin yol cerrahi seçenektir. Kesin kabul edilen tanımı olmamakla beraber metabolik cerrahi, metabolik sendromu tedavi etmek için yapılan cerrahi müdahaleler olarak tarif edilebilir. Genel algı bariatrik cerrahi geçiren hasta kişilerin kilo vermeyle ilişkili tip 2 diyabet hastalığının remisyona girmesidir. Ameliyat sonrası bu hastalar hastanede yatarken kan şeker değerlerinin düzelmeye başladığı görülmüştür. Kan glukozu dengelenmesinde gastrointestinal sistemin önemli rol aldığı anlaşılınca, mekanizmasının ortaya çıkması için çalışmalar yapılmıştır. Ön ve arka barsak hipotezleri ortaya atılmıştır. Arka barsak ameliyatı olan Duodenalswitch’in ön barsak ameliyatı olan gastrik by-pass’a göre hiperinsülinemik cevaba neden olmadan glukoz dengesini ve insülin duyarlılığında iyileşme sağladığı ortaya konmuştur. Arka barsak modulasyonu yapılan ameliyatlar, ön barsak modülasyonu yapılan ameliyatlara göre mineral-vitamin dengesini daha çok bozma eğilimindedir. Son zamanlarda bunu önlemek için transit bipartisyon ameliyatı geliştirilmiştir. Sonuçta metabolik cerrahi ameliyatlarında değişik teknikler tercih edilmektedir. Yapılacak ameliyat yönteminin kişiye özel olması gerektir.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Janković D, Wolf P, Anderwald CH, Winhofer Y, PromintzerSchifferl M, Hofer A, et al. Prevalence of endocrine disorders in morbidly obese patients and the effects of bariatric surgery on endocrine and metabolic parameters. Obes Surg 2012;22(1):62–9.
  • 2. Elshaer M, Hamaoui K, Rezai P, Ahmed K, Mothojakan N, Al-Taan O. Secondary Bariatric Procedures in a High-Volume Centre: Prevalence, Indications and Outcomes. Obes Surg 2019;29(7):2255–2262.
  • 3. Cottam S, Cottam D, Cottam A. Sleeve Gastrectomy Weight Lossand the preoperative and postoperative predictors: A systematic Review. Obes Surg 2019;29(4):1388–1396.
  • 4. Worm D, Madsbad S, Hansen DL. Metabolic Healthy in severely obese subjects: A Descriptive study. Metab Syndr Relat Disord 2019;17(2):115–119.
  • 5. Wang L, Wang J, Jiang T. Effect of Laparoscopic Sleeve Gastrectomy on Type 2 Diabetes Mellitus in patients with Body Mass Index less than 30 kg/m2. ObesSurg 2019;29(3):835–842.
  • 6. Rubino F, Shukla A, Pomp A, Moreira M, Ahn S. M, Dakin G, et al. Bariatric, metabolic, and diabetes surgery: what’s in a name? Ann Surg 2014;259:117–22.
  • 7. Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. AnnSurg 2006;244:741–9.
  • 8. Nora M, Guimarães M, Almeida R, Martins P, Gonçalves G, Santos M, et al. Excess Body Mass Index Loss Predicts Metabolic Syndrome Remission After Gastric Bypass Diabetol Metab Syndr 2014 2;6(1):1.
  • 9. Cazzo E, Gestic MA, Utrini MP, Machado RR, Geloneze B, Pareja JC, et al. Impact of Roux-en-Y-Gastric Bypass on Metabolic Syndrome and Insulin Resistance Parameters. Diabetes Technol Ther 2014;16(4):262–5.
  • 10. Li JF, Lai DD, Ni B, Sun KX. Comparison of Laparoscopic Roux-en-Y Gastric Bypass With Laparoscopic Sleeve Gastrectomy for Morbid Obesity or Type 2 Diabetes Mellitus: A Meta-Analysis of Randomised Controlled Trials. Can J Surg 2013;56(6):158–64.
  • 11. Aftab H, Risstad H, Søvik TT, Bernklev T, Hewitt S, Kristinsson JA, et al. Five-year Outcome After Gastric Bypass for Morbid Obesity in a Norwegian Cohort. Surg Obes Relat Dis 2014 J; 10(1):71–8.
  • 12. Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, MingroneG, et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ 2013 22;347: f5934.
  • 13. Desiderio J, Trastulli S, Scalercio V, Mirri E, Grandone I, Cirocchi R, et al. Effects of laparoscopic sleeve gastrectomy in patients with morbid obesity and metabolic disorders. Diabetes Technol Ther 2013;15(12):1004–9.
  • 14. Neff KJ, le Roux CW. Bariatric Surgery: The indications in Metabolic Disease. Neff KJ, le Roux CW. DigSurg 2014;31(1):6–12.
  • 15. Williams S, Cunningham E, Pories WJ. Surgical Treatment of metabolic syndrome Med Princ Pract 2012;21(4):301–9.
  • 16. Gass M, Beglinger C, Peterli R. Metabolic Surgery-Principles and Current concepts Langenbecks Arch Surg 2011;396(7):949–72.
  • 17. Sabench Pereferrer F, Hernàndez Gonzàlez M, Del Castillo Déjardin D. Experimental Metabolic Surgery: Justification and Technical Aspects Obes Surg 2011;21(10):1617–28.
APA CIFTCI F (2021). What is Metabolic Surgery? To Whom and When Should It Be Applied?. , 332 - 335. 10.5505/kjms.2021.43403
Chicago CIFTCI FATIH What is Metabolic Surgery? To Whom and When Should It Be Applied?. (2021): 332 - 335. 10.5505/kjms.2021.43403
MLA CIFTCI FATIH What is Metabolic Surgery? To Whom and When Should It Be Applied?. , 2021, ss.332 - 335. 10.5505/kjms.2021.43403
AMA CIFTCI F What is Metabolic Surgery? To Whom and When Should It Be Applied?. . 2021; 332 - 335. 10.5505/kjms.2021.43403
Vancouver CIFTCI F What is Metabolic Surgery? To Whom and When Should It Be Applied?. . 2021; 332 - 335. 10.5505/kjms.2021.43403
IEEE CIFTCI F "What is Metabolic Surgery? To Whom and When Should It Be Applied?." , ss.332 - 335, 2021. 10.5505/kjms.2021.43403
ISNAD CIFTCI, FATIH. "What is Metabolic Surgery? To Whom and When Should It Be Applied?". (2021), 332-335. https://doi.org/10.5505/kjms.2021.43403
APA CIFTCI F (2021). What is Metabolic Surgery? To Whom and When Should It Be Applied?. Kafkas Tıp Bilimleri Dergisi, 11(2), 332 - 335. 10.5505/kjms.2021.43403
Chicago CIFTCI FATIH What is Metabolic Surgery? To Whom and When Should It Be Applied?. Kafkas Tıp Bilimleri Dergisi 11, no.2 (2021): 332 - 335. 10.5505/kjms.2021.43403
MLA CIFTCI FATIH What is Metabolic Surgery? To Whom and When Should It Be Applied?. Kafkas Tıp Bilimleri Dergisi, vol.11, no.2, 2021, ss.332 - 335. 10.5505/kjms.2021.43403
AMA CIFTCI F What is Metabolic Surgery? To Whom and When Should It Be Applied?. Kafkas Tıp Bilimleri Dergisi. 2021; 11(2): 332 - 335. 10.5505/kjms.2021.43403
Vancouver CIFTCI F What is Metabolic Surgery? To Whom and When Should It Be Applied?. Kafkas Tıp Bilimleri Dergisi. 2021; 11(2): 332 - 335. 10.5505/kjms.2021.43403
IEEE CIFTCI F "What is Metabolic Surgery? To Whom and When Should It Be Applied?." Kafkas Tıp Bilimleri Dergisi, 11, ss.332 - 335, 2021. 10.5505/kjms.2021.43403
ISNAD CIFTCI, FATIH. "What is Metabolic Surgery? To Whom and When Should It Be Applied?". Kafkas Tıp Bilimleri Dergisi 11/2 (2021), 332-335. https://doi.org/10.5505/kjms.2021.43403